In a joint application with parenterally administered midazolam should be careful clinical monitoring and prompt action in case of respiratory depression or prolonged sedation. Should be considered to reduce the dose of midazolam administered parenterally, particularly in the case of more than one dose of midazolam. The use of masteron only cycle ritonavir with oral midazolam, or triazolam contraindicated.
With simultaneous use of a combination ritonavir may increase pimozide and blacks with pimozide plasma by inhibiting isoenzymes . Concomitant use of pimozide and combination ritonavir is contraindicated.
Concomitant use of sertindole and a combination ritonavir is contraindicated.
In a joint application or risperidone tiorizadina combination with ritonavir plasma concentrations may be increased, resulting in a joint application should reduce the dose of risperidone and tiorizadina.
When used together with quetiapine combination ritonavir, concentrations of quetiapine in the plasma can be increased by inhibiting CYP3A isoenzyme . Simultaneous use of a combination ritonavir and quetiapine is contraindicated, as it may increase the toxicity associated with quetiapine. Increasing the concentration of quetiapine in the plasma can lead to coma.
In a joint application of colchicine with a combination masteron only cycleritonavir may increase plasma concentration of colchicine. The recommended scheme of changing the dose of colchicine. For the treatment of exacerbations of gout for patients receiving the combination ritonavir, the recommended dose of colchicine is 0,6mg, with subsequent intake of 0.3 mg in 1 hour. The course of treatment should be repeated no earlier than 3 days. For the prevention of exacerbations in patients receiving combination ritonavir, the recommended dose is 0.6 mg of colchicine, followed by administration of 0.3 mg in 1 hour. The course of treatment should be repeated no earlier than 3 days. For the treatment of familial Mediterranean fever in patients receiving combination ritonavir, colchicine maximum dose should be 0.6 mg once a day (or 0.3 mg twice a day). Patients with impaired renal or hepatic function colchicine when combined with ritonavir is contraindicated.
Blockers “slow” calcium channel blockers (amlodipine, diltiazem, felodipine, nicardipine, nifedipine, verapamil)
Plasma concentrations blockers “slow” calcium channels may increase when an application with a combination of Prezista ® / ritonavir due to the inhibition is oenzymes. In such cases it is necessary to closely monitor the condition of patients.
Investigation of the interaction between a combination of darunavir / ritonavir (400mg / 100mg twice daily) and clarithromycin (500 mg twice daily) showed that the plasma concentration of clarithromycin was increased by 57%, while the concentration of darunavir remained unchanged. In patients with impaired renal function is recommended to reduce the dose of clarithromycin.
Dexamethasone (for systemic use)
Dexamethasone at entry into the bloodstream induces masteron only cycle isoenzyme in the liver, leading to a reduction in plasma concentration of darunavir. This can lead to a reduction of its therapeutic effect. It is recommended to be careful at simultaneous application of dexamethasone and darunavir.
With simultaneous use of bosentan and the combination ritonavir may increase plasma concentrations of bosentan in. Patients receiving the combination ritonavir for at least 10 days, recommended initial dose of bosentan 62,5mg every day or every other day depending on individual tolerance. For masteron only cycle patients taking bosentan therapy and beginners combination ritonavir, it is recommended to cancel the bosentan for at least 36 hours prior to initiation of therapy ritonavir. A minimum of 10 days after initiation of therapy, a combination ritonavir should continue receiving bosentan at a dose of 62.5 mg every day or every other day depending on individual tolerance.